Cognitive Impairment Tied to Heart Disease
Study included were 9,901 adults from 24 countries with established or newly diagnosed type 2 diabetes, with an HbA1c of 9.5% or less. After approximately 5 years of follow-up, those who received weekly injections of 1.5 mg of dulaglutide had a 12% reduced risk for experiencing the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes compared with those in the placebo group (HR 0.88, 95% CI 0.79-0.99, P=0.026). he new post-hoc analysis included 8,772 participants from 24 countries who completed both the Montreal Cognitive Assessment (MoCA) and the Digit Substitution Test (DSST) at baseline.

In 8,772 patients from the REWIND trial followed for approximately 5 years, those with substantive cognitive impairment had a greater risk for major cardiovascular events such as myocardial infarction (HR 1.30, 95% CI 1.11-1.62, P=0.003) as well as the composite of stroke or death (HR 1.60, 95% CI 1.33-1.91, P<0.001).

Analysis showed cognitive impairment predicted risk for major cardiovascular events, stroke, and death in patients with type 2 diabetes.